Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 +6.3%	$1.22	$0.86 ▼ $3.78	$264.04M	0.35	4.41 million shs	7.30 million shs
CBPO China Biologic Products	$119.99	$119.23	$99.74 ▼ $120.05	$4.72B	0.47	148,695 shs	390,921 shs
REPL Replimune Group	$5.67 +1.3%	$7.87	$2.68 ▼ $17.00	$442.58M	0.67	4.07 million shs	2.27 million shs
SWTX SpringWorks Therapeutics	$46.99	$46.90	$28.21 ▼ $62.00	$3.54B	0.68	2.66 million shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+5.66%	+4.67%	-21.13%	+5.66%	-59.12%
CBPO China Biologic Products	0.00%	0.00%	0.00%	0.00%	0.00%
REPL Replimune Group	+6.67%	+4.67%	+99.29%	-32.93%	-45.47%
SWTX SpringWorks Therapeutics	0.00%	0.00%	0.00%	+1.10%	+18.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.878 of 5 stars	3.4	3.0	0.0	0.0	2.2	2.5	0.6
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	4.4479 of 5 stars	4.2	2.0	0.0	4.5	1.7	2.5	0.6
SWTX SpringWorks Therapeutics	0.369 of 5 stars	2.1	0.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	609.62% Upside
CBPO China Biologic Products	0.00	N/A	N/A	N/A
REPL Replimune Group	2.33	Hold	$7.67	35.21% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside

Current Analyst Ratings Breakdown

Latest SWTX, CBPO, REPL, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00
7/22/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$19.00 ➝ $9.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,201.86	N/A	N/A	$1.55 per share	0.77
CBPO China Biologic Products	$503.70M	9.38	$5.01 per share	23.93	$45.09 per share	2.66
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
CBPO China Biologic Products	$138.81M	$4.28	33.52	27.90	N/A	27.43%	8.32%	7.64%	N/A
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	N/A
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	N/A

Latest SWTX, CBPO, REPL, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
CBPO China Biologic Products	N/A	12.01	10.13
REPL Replimune Group	0.21	6.94	6.94
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CBPO China Biologic Products	34.77%
REPL Replimune Group	92.53%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CBPO China Biologic Products	2.73%
REPL Replimune Group	5.20%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
CBPO China Biologic Products	2,269	39.36 million	N/A	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

SWTX, CBPO, REPL, and ALLO Headlines

Recent News About These Companies

SpringWorks Therapeutics Receives European Commission Approval for OGSIVEO® (nirogacestat) as the First Treatment for Desmoid Tumors

August 18, 2025 | quiverquant.comQ

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

August 18, 2025 | globenewswire.com

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

August 18, 2025 | globenewswire.com

European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients

July 18, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

July 18, 2025 | quiverquant.comQ

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025 | globenewswire.com

SpringWorks Therapeutics Completes Merger and Delisting

July 1, 2025 | tipranks.com

SpringWorks Therapeutics Inc (SWTX) - Investing.com

June 28, 2025 | investing.com

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 26, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

HC Wainwright & Co. Downgrades SpringWorks Therapeutics (SWTX)

May 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SWTX, CBPO, REPL, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.19 +0.07 (+6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.03 (+2.52%)

As of 07:01 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Replimune Group NASDAQ:REPL

$5.67 +0.07 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$5.73 +0.06 (+1.13%)

As of 07:15 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

SpringWorks Therapeutics NASDAQ:SWTX

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time